Literature DB >> 6777836

The development of mesna for the inhibition of urotoxic side effects of cyclophosphamide, ifosfamide, and other oxazaphosphorine cytostatics.

N Brock.   

Abstract

Urotoxic side effects on the kidneys and urinary bladder are a limiting factor in chemotherapy with oxazaphosphorine cytostatics such as cyclophosphamide and ifosfamide. Acrolein was found to be the causative factor which is spontaneously formed in the urine from the primary metabolites eliminated via the kidneys. Sodium 2-mercaptoethanesulfonate (INN: mesna) enables regional detoxification of acrolein in the kidneys and deferent urinary tract. The author reports on the pharmacotherapeutic bases and the mechanism of action of this new combination therapy and its clinical results. The untoward urotoxic side effects can be avoided with mesna without interfering with the chemotherapeutic effect on the tumor.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6777836     DOI： 10.1007/978-3-642-81488-4_32

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN： 0080-0015


  9 in total

1.  Carcinogenic effect of cisplatin (cis-diammine-dichloroplatinum (II), CDDP) in BD IX rats.

Authors:  S R Kempf; S Ivankovic
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

2.  Formation, toxicity and inactivation of acrolein during biotransformation of cyclophosphamide as studied in freshly isolated cells from rat liver and kidney.

Authors:  Y Ohno; K Ormstad
Journal:  Arch Toxicol       Date:  1985-06       Impact factor: 5.153

Review 3.  Late effects on the urinary bladder in patients treated for cancer in childhood: a report from the Children's Oncology Group.

Authors:  Michael Ritchey; Fernando Ferrer; Patricia Shearer; Sheri L Spunt
Journal:  Pediatr Blood Cancer       Date:  2009-04       Impact factor: 3.167

4.  Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals.

Authors:  Ryan J Hansen; Susan M Ludeman; Sari J Paikoff; Anthony E Pegg; M Eileen Dolan
Journal:  DNA Repair (Amst)       Date:  2007-05-07

5.  Flow-cytophotometric studies on urine sediments of patients treated with anti-cancer-drugs.

Authors:  H W Schwabe; H D Adolphs; J Hartlapp
Journal:  Urol Res       Date:  1983

6.  Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment.

Authors:  G Falkson; J J Van Dyk; R Stapelberg; H C Falkson
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

7.  Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling.

Authors:  Naoyuki Nishiya; Moeka Murai; Ayumi Hosoda; Honami Yonezawa; Norikazu Omori
Journal:  Pharmaceuticals (Basel)       Date:  2019-11-07

8.  Targeting adaptor protein SLP76 of RAGE as a therapeutic approach for lethal sepsis.

Authors:  Zhengzheng Yan; Haihua Luo; Bingyao Xie; Tian Tian; Shan Li; Zhixia Chen; Jinghua Liu; Xuwen Zhao; Liyong Zhang; Yongqiang Deng; Timothy R Billiar; Yong Jiang
Journal:  Nat Commun       Date:  2021-01-12       Impact factor: 14.919

9.  Effective prevention of the nephrotoxicity of cis-platin (CDDP) by administration of sodium 2-mercaptoethane-sulfonate (MESNA) in rats.

Authors:  S R Kempf; S Ivankovic; M Wiessler; D Schmähl
Journal:  Br J Cancer       Date:  1985-12       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.